A detailed history of Jane Street Group, LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 43,998 shares of SRPT stock, worth $4.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,998
Previous 869,129 94.94%
Holding current value
$4.88 Million
Previous $137 Million 96.0%
% of portfolio
0.0%
Previous 0.16%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$124.33 - $156.75 $103 Million - $129 Million
-825,131 Reduced 94.94%
43,998 $5.5 Million
Q2 2024

Aug 14, 2024

BUY
$113.33 - $163.85 $67 Million - $96.8 Million
591,025 Added 212.52%
869,129 $137 Million
Q1 2024

May 15, 2024

BUY
$93.7 - $141.53 $8.95 Million - $13.5 Million
95,472 Added 52.28%
278,104 $36 Million
Q4 2023

Feb 14, 2024

BUY
$67.31 - $124.76 $6.62 Million - $12.3 Million
98,280 Added 116.51%
182,632 $17.6 Million
Q3 2023

Nov 14, 2023

SELL
$102.5 - $123.59 $6 Million - $7.23 Million
-58,531 Reduced 40.96%
84,352 $10.2 Million
Q2 2023

Aug 14, 2023

BUY
$106.4 - $157.19 $254,615 - $376,155
2,393 Added 1.7%
142,883 $16.4 Million
Q1 2023

May 15, 2023

SELL
$117.53 - $155.99 $3.96 Million - $5.25 Million
-33,674 Reduced 19.33%
140,490 $19.4 Million
Q4 2022

Feb 14, 2023

BUY
$100.86 - $132.13 $8.61 Million - $11.3 Million
85,327 Added 96.05%
174,164 $22.6 Million
Q3 2022

Nov 14, 2022

BUY
$75.71 - $119.24 $602,878 - $949,508
7,963 Added 9.85%
88,837 $9.82 Million
Q2 2022

Aug 16, 2022

BUY
$62.69 - $88.44 $3.98 Million - $5.61 Million
63,482 Added 365.01%
80,874 $6.06 Million
Q1 2022

May 17, 2022

SELL
$63.15 - $90.42 $9.35 Million - $13.4 Million
-148,032 Reduced 89.49%
17,392 $1.36 Million
Q4 2021

Feb 15, 2022

BUY
$77.28 - $99.42 $3.48 Million - $4.47 Million
44,998 Added 37.37%
165,424 $14.9 Million
Q3 2021

Nov 16, 2021

BUY
$65.97 - $92.48 $5.22 Million - $7.32 Million
79,201 Added 192.12%
120,426 $11.1 Million
Q2 2021

Aug 16, 2021

SELL
$69.38 - $86.75 $8.76 Million - $11 Million
-126,321 Reduced 75.39%
41,225 $3.21 Million
Q1 2021

May 18, 2021

BUY
$72.25 - $168.95 $8.26 Million - $19.3 Million
114,298 Added 214.65%
167,546 $12.5 Million
Q4 2020

Feb 17, 2021

BUY
$125.56 - $178.74 $4.33 Million - $6.16 Million
34,451 Added 183.28%
53,248 $9.08 Million
Q3 2020

Nov 17, 2020

BUY
$127.12 - $172.34 $381,232 - $516,847
2,999 Added 18.98%
18,797 $2.64 Million
Q2 2020

Aug 17, 2020

BUY
$93.0 - $171.7 $287,742 - $531,239
3,094 Added 24.35%
15,798 $2.53 Million
Q1 2020

May 15, 2020

BUY
$82.38 - $131.64 $664,724 - $1.06 Million
8,069 Added 174.09%
12,704 $1.24 Million
Q4 2019

Feb 14, 2020

SELL
$76.53 - $135.58 $150,687 - $266,957
-1,969 Reduced 29.82%
4,635 $598,000
Q3 2019

Nov 14, 2019

SELL
$72.81 - $156.91 $10.7 Million - $23.1 Million
-147,490 Reduced 95.71%
6,604 $498,000
Q2 2019

Aug 15, 2019

BUY
$112.21 - $151.95 $12.1 Million - $16.4 Million
108,092 Added 234.97%
154,094 $23.4 Million
Q1 2019

May 16, 2019

BUY
$106.67 - $151.68 $3.14 Million - $4.46 Million
29,395 Added 177.0%
46,002 $5.48 Million
Q4 2018

Feb 15, 2019

BUY
$97.32 - $148.76 $1.29 Million - $1.97 Million
13,248 Added 394.4%
16,607 $1.81 Million
Q3 2018

Nov 14, 2018

SELL
$115.31 - $161.51 $15.4 Million - $21.6 Million
-133,903 Reduced 97.55%
3,359 $543,000
Q2 2018

Aug 15, 2018

BUY
$71.74 - $153.69 $7.96 Million - $17.1 Million
110,975 Added 422.17%
137,262 $18.1 Million
Q1 2018

May 15, 2018

SELL
$54.02 - $82.27 $71,306 - $108,596
-1,320 Reduced 4.78%
26,287 $1.95 Million
Q4 2017

Feb 15, 2018

SELL
$47.64 - $56.75 $1.89 Million - $2.25 Million
-39,587 Reduced 58.91%
27,607 $1.54 Million
Q3 2017

Nov 14, 2017

BUY
$35.73 - $47.15 $2.4 Million - $3.17 Million
67,194
67,194 $3.05 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.71B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.